Albumin interferon alfa-2b dosed at Q2W or Q4W intervals demonstrates comparable week 12 efficacy response in IFN naive, genotype-1 rapid viral responders

被引：0
|
作者：
Neumann, A. U.
Rozenberg, L.
Zeuzem, S.
Benhamou, Y.
McHutchison, J.
Pulkstenis, E.
Subramanian, M.
机构：
[1] Bar Ilan Univ, Ramat Gan, Israel
[2] Univ Saarland, D-6600 Saarbrucken, Germany
[3] Hop La Pitie Salpetriere, Paris, France
[4] Duke Clin Res Inst, Durham, NC USA
[5] Human Genome Sci Inc, Rockville, MD USA
来源：
JOURNAL OF HEPATOLOGY | 2007年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
624
引用
收藏
页码：S236 / S236
页数：1
相关论文
共 11 条
  • [1] Comparable antiviral response rates with albumin interferon alfa-2b dosed at Q2W or Q4W intervals in naive subjects with genotype 2 or 3 chronic hepatitis C
    Bain, V. G.
    Marotta, P.
    Kaita, K.
    Yoshida, E.
    Swain, M.
    Bailey, R.
    Neumann, A.
    Cronin, P.
    McHutchison, J.
    Pulkstenis, E.
    Subramanian, M.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S7 - S7
  • [2] PHASE 2 STUDY OF TELAPREVIR ADMINISTERED Q8H OR Q12H WITH PEGINTERFERON-ALFA-2A OR -ALFA-2B AND RIBAVIRIN IN TREATMENT-NAiVE SUBJECTS WITH GENOTYPE 1. HEPATITIS C: WEEK 4 INTERIM RESULTS (vol 48, pg 4, 2008)
    Forns, X.
    Marcellin, P.
    Goeser, T.
    Ferenci, P.
    Nevens, F.
    Carosi, G.
    Drenth, J. P.
    De Backer, K.
    van Heeswijk, R.
    Vangeneugden, T. J.
    Picchio, G.
    Beumont-Mauviel, M.
    HEPATOLOGY, 2008, 48 (06) : 2093 - 2093
  • [3] Favorable quality of life (QOL) in the first 12 weeks of treatment with albumin interferon alfa-2b compared with PEG-IFN in a Phase 2b study conducted in a genotype 1, IFN-naive, chronic hepatitis C subjects
    Pianko, S.
    Sievert, W.
    Subramanian, M.
    McHutchison, J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A309 - A309
  • [4] PHASE 2 STUDY OF TELAPREVIR ADMINISTERED Q8H OR Q12H WITH PEGINTERFERON-ALFA-2A OR-ALFA-2B AND RIBAVIRIN IN TREATMENT-NAiVE SUBJECTS WITH GENOTYPE 1 HEPATITIS C: WEEK 4 INTERIM RESULTS
    Forns, Xavier
    Marcellin, Patrick
    Goeser, Tobias
    Ferenci, Peter
    Nevens, Frederik
    Carosi, Giampiero
    Drenth, Joost P.
    De Backer, Koen
    van Heeswijk, Rudolf
    Vangeneugden, Tony J.
    Picchio, Gaston
    Beumont-Mauviel, Maria
    HEPATOLOGY, 2008, 48 (04) : 1136A - 1137A
  • [5] Safety and Sustained Viral Response of MK-5172 for 12 Weeks in Combination With Pegylated Interferon Alfa-2B and Ribavirin for 24 Weeks in HCV Genotype 1 Treatment-Naive Noncirrhotic Patients
    Marcellin, Patrick
    Vierling, John M.
    Bacon, Bruce R.
    Manns, Michael P.
    Fandozzi, Christine M.
    Gress, Jacqueline
    Gilbert, Christopher L.
    Hwang, Peggy
    Wahl, Janice
    Cooreman, Michael
    Mobashery, Niloufar
    HEPATOLOGY, 2012, 56 : 561A - 561A
  • [6] On-Treatment Response-Guided Therapy With Telaprevir Q8h or Q12h Combined With Peginterferon Alfa-2a or Peginterferon Alfa-2B and Ribavirin in Treatment-NaiVE Genotype 1 Hepatitis C (Study C208)
    Marcellin, Patrick
    Forns, Xavier
    Goeser, Tobias
    Ferenci, Peter
    Nevens, Frederik
    Carosi, Giampiero
    Drenth, Joost P. H.
    Serfaty, Lawrence
    De Backer, Koen
    van Heeswijk, Rolf
    Luo, Don
    De Meyer, Sandra
    Beumont-Mauviel, Maria
    GASTROENTEROLOGY, 2010, 138 (05) : S847 - S847
  • [7] ON-TREATMENT RESPONSE-GUIDED THERAPY WITH TELAPREVIR Q8H OR Q12H COMBINED WITH PEGINTERFERON ALFA-2A PEGINTERFERON ALFA-2B AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HEPATITIS C (STUDY C208)
    Forns, X.
    Marcellin, P.
    Ferenci, P.
    Goeser, T.
    Nevens, F.
    Carosi, G.
    Drenth, J. P.
    Serfaty, L.
    De Backer, K.
    van Heeswijk, R.
    Luo, D.
    Picchio, G.
    Beaumont, M.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S26 - S26
  • [8] HIGH SUSTAINED VIRAL RESPONSE AT 12-AND 24-WEEK FOLLOW-UP OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS
    Manns, M.
    Vierling, J. M.
    Bacon, B. R.
    Marcellin, P.
    Caro, L.
    Gress, J.
    Gilbert, C.
    Cooreman, M. P.
    Robertson, M.
    Hwang, P.
    Wahl, J.
    Mobashery, N.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S30 - S30
  • [9] TELAPREVIR (TVR) q8h OR q12h COMBINED WITH EITHER PEGINTERFERON (PEG-IFN, P) ALFA-2A OR ALFA-2B AND RIBAVIRIN (RBV, R) IN TREATMENT-NAIVE GENOTYPE 1 HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY C208
    Colombo, M.
    Rumi, M. G.
    Carosi, G.
    Puoti, M.
    Marcellin, P.
    Forns, X.
    Goeser, T.
    Ferenci, P.
    Nevens, F.
    Drenth, J. P.
    Serfaty, L.
    Beumont-Mauviel, M.
    Picchio, G.
    DIGESTIVE AND LIVER DISEASE, 2010, 42 : S6 - S7
  • [10] PEGYLATED INTERFERON LAMBDA (PEG-IFN-λ) PHASE 2 DOSE-RANGING, ACTIVE-CONTROLLED STUDY IN COMBINATION WITH RIBAVIRIN (RBV) FOR TREATMENT-NAiVE HCV PATIENTS (GENOTYPES 1, 2, 3 OR 4): SAFETY, VIRAL RESPONSE, AND IMPACT OF IL-28B HOST GENOTYPE THROUGH WEEK 12
    Muir, Andrew J.
    Lawitz, Eric
    Ghalib, Reem H.
    Sussman, Norman L.
    Anderson, Frank
    Everson, Gregory T.
    Jacobson, Ira M.
    Lopez-Talavera, Juan Carlos
    Hillson, Jan L.
    Gray, Todd E.
    Fontana, David
    Ramos, Eleanor L.
    Rodriguez-Torres, Maribel
    HEPATOLOGY, 2010, 52 (04) : 715A - 716A
12